Novo Nordisk's Two-Speed Reality: Operations Improve While Investor Confidence Slips Away
Published on 08/06/2026 at 19:12 | Redaktion boerse-global.de
The arithmetic of Novo Nordisk's week is deceptively simple: the Danish drugmaker lifted its full-year guidance, delivered second-quarter numbers that beat expectations, and still watched its share price get battered. On Tuesday, the stock tumbled as much as 7.1 percent in Copenhagen despite the improved outlook — a move that the options market had only partially anticipated, with Saxo Bank noting that traders had priced in a swing of roughly 8 percent ahead of the August 5 results. Two days later, the shares were changing hands at 39.25 euros, up 1.38 percent on the day but still nursing a weekly loss of 12.17 percent. The contrast between operational delivery and market reception has rarely been starker.
The Numbers Tell One Story
Stripped of the noise, the underlying business is performing. Novo Nordisk reported adjusted revenue of 78.488 billion Danish kroner for the second quarter, a 7 percent increase on a constant-exchange-rate basis, while adjusted operating profit climbed 11 percent to 33.389 billion kroner. Management used the occasion to narrow its full-year guidance for both revenue and operating profit growth to a range of 0 to minus 6 percent, a meaningful improvement from the previous minus 4 to minus 12 percent projection. The share buyback program, meanwhile, continues to grind forward: as of August 3, the company had repurchased more than 27 million B-shares for 7.5 billion kroner under its 15 billion kroner, twelve-month authorization.
Yet none of this moved the needle in the way management would have hoped. The market's skepticism, it seems, is no longer about the current year — it is about what comes after.
The Pipeline Is the Problem
The second-quarter report carried a non-cash impairment charge of 6.3 billion kroner tied to pipeline assets, including 4.0 billion kroner for the discontinued monlunabant program. That write-down alone signaled that not everything in development is working. But the more consequential blow landed on Wednesday, when the Phase 3 Reimagine-4 trial for CagriSema delivered mixed results: the drug achieved its co-primary endpoint on weight loss with a 15.2 percent reduction, narrowly trailing Eli Lilly's tirzepatide at 15.8 percent, but missed the mark on glycemic control — a 1.9 percent HbA1c reduction versus 2.2 percent for the competitor. For a candidate long positioned as Novo Nordisk's answer to Lilly's momentum, the failure to demonstrate non-inferiority on blood sugar control was a significant setback.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The ZEUS study added to the gloom. Earlier in the week, the company confirmed that ziltivekimab had failed to meet its primary endpoint — a significant reduction in major adverse cardiovascular events among patients with atherosclerosis and chronic kidney disease. Notably, the secondary article's account of the ZEUS results differs, describing the trial as having achieved a significant reduction in cardiovascular risk; the primary article, however, reports the primary endpoint was missed, and that account is used here as the more detailed and specific version of events.
Analysts Rewrite Their Models
The research community has responded by marking down their valuations. Morningstar cut its fair value estimate for the stock from 311 to 285 Danish kroner, citing lower long-term gross margin assumptions and disappointment with CagriSema's performance against Lilly's products. At Jefferies, analyst Michael Leuchten said the quarterly numbers and the soft launch trajectory of the Wegovy pill relative to elevated expectations leave "many questions open" about the company's competitiveness heading into 2027. Barclays' James Gordon also adjusted his estimates following the results and the revised guidance.
The direction of travel is telling: even with an upgraded forecast, valuation models are moving downward, not upward. Pipeline risk has come to overshadow operational strength.
Small Wins, Bigger Questions
It has not been an entirely bleak stretch. A Dutch court issued an injunction on Wednesday against Ceban Ziekenhuisfarmacie, barring the pharmacy from producing and selling a compounded semaglutide nasal spray that infringed Novo Nordisk's patent rights — a modest but meaningful victory in the company's ongoing battle against copycat products. The Phase 3 HIBISCUS trial for etavopivat concluded successfully on Tuesday, and a new Phase 3 study, HF-POLARIS, has launched to evaluate zenagamtide in heart failure. The company also announced a partnership with health-data firm H1 to use AI-powered workflows for faster, more targeted clinical trial recruitment. And in July, the European Commission approved the Wegovy pill as the first oral GLP-1 treatment for weight management in the EU, alongside a 7.2 mg pre-filled pen.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
None of these developments, however, has been enough to reset the narrative. The shares remain 27.72 percent below their 52-week high, and the roughly 11 percent weekly decline speaks to how quickly investor confidence can erode when a pipeline story fractures on multiple fronts simultaneously.
A Defining Moment in September
All eyes now turn to the Capital Markets Day scheduled for September 21, where Novo Nordisk is expected to lay out its long-term strategy and financial targets. The company needs to do more than present a revised outlook — it needs to rebuild credibility around a pipeline that has lost some of its luster. The operating engine is running smoothly; the question is whether the growth narrative can be repaired before the market's patience runs out entirely. For now, the stock sits in an uncomfortable middle ground: too well-run to be abandoned, too uncertain to be embraced.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
